Posts Tagged ‘American Cancer Society’

Bonnie J. Addario Lung Cancer Foundation Honors Novartis for its Contributions to Lung Cancer Research and Development

Posted: Nov 10, 2014 | Posted by Kassy Perry | Comments Off on Bonnie J. Addario Lung Cancer Foundation Honors Novartis for its Contributions to Lung Cancer Research and Development

Novartis to receive the “Simply the Best” award at the ALCF Gala on November 8

San Carlos, Calif. (November 8, 2014)– The Bonnie J. Addario Lung Cancer Foundation (ALCF) will honor Novartis today for its dedication and recent breakthroughs in lung cancer research and development. Novartis will receive the “Simply the Best” award at the ALCF’s Annual Gala taking place in San Francisco.

“Lung cancer is the top cancer killer worldwide and patients’ five-year survival rate remains stagnant at 16 percent,” said Bonnie J. Addario, founder of the ALCF and a stage 3B lung cancer survivor. “Research and development is essential to change the survival rate and we are excited about Novartis’ medical advancements – it’s a big step forward for people with lung cancer.”

In April, Novartis received Food and Drug Administration (FDA) early approval for an ALK inhibitor following the FDA’s Breakthrough Therapy Designation. Novartis recently expanded its efforts in the field of immunotherapy, specifically for non-small cell lung cancer. In October, the company announced a clinical collaboration with Bristol-Myers Squibb (BMS) to study several of Novartis’ molecularly targeted compounds in combination with an immunotherapy agent from BMS. All are steps to help patients in their fight against lung cancer through the development of medicines that can help target the deadly disease with an individualized approach.
READ MORE

New Clinical Study Aims to Investigate the Genomics of Young Lung Cancer

Posted: Jul 25, 2014 | Posted by Kassy Perry | Comments Off on New Clinical Study Aims to Investigate the Genomics of Young Lung Cancer

Addario Lung Cancer Medical Institute Puts Spotlight on Lung Cancer in Young Adults

San Carlos, Calif. (July 23, 2014)– The Addario Lung Cancer Medical Institute (ALCMI) today launched a new study, the Genomics of Young Lung Cancer, to understand why lung cancer occurs in young adults, who quite often are athletic, never smokers and do not exhibit any of the known lung cancer genetic mutations. ALCMI, a patient-centric, international research consortium and partner of the Bonnie J. Addario Lung Cancer Foundation (ALCF), is facilitating this first-of-its-kind, multi- institutional, prospective genomic study in order to identify new genome-defined subtypes of lung cancer and accelerate delivery of more effective targeted therapies.

“It’s heartbreaking when you meet young adults with lung cancer, who should have their full lives ahead of them but instead are fighting for their lives because of the lack of lung cancer treatments,” said Bonnie J. Addario, stage 3B lung cancer survivor and founder of ALCMI and the ALCF. “This groundbreaking study will investigate why young adults under the age of 40 are getting lung cancer and whether they have a unique cancer subtype, or genotype, that can be treated differently.”
READ MORE

California Companies Target Heart Disease, Cancer With More Than 240 Medicines in Development

Posted: May 23, 2011 | Posted by Kassy Perry | No Comments

WASHINGTON–(BUSINESS WIRE)–At a time when cancer and heart disease are the nation’s and the world’s top killers, biopharmaceutical research companies headquartered in California are developing 243 of the 1,186 medicines in development for those dreaded diseases.

The California companies are developing 188 of 887 drugs for more than 20 types of cancer and 55 of 299 medicines for heart disease and stroke.

The cancer statistics are contained in a new report “Medicines in Development for Cancer” published by the Pharmaceutical Research and Manufacturers of America (PhRMA), while the data on heart disease and stroke are from a PhRMA report from early this year.

The cancer report and “Medicines in Development for Heart Disease and Stroke” can be found on the PhRMA website, www.phrma.org.
READ MORE